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Our results presented here demonstrate that the most abundant human papillomavirus type 16 (HPV-16)
mRNAs expressing the viral oncogenes E6 and E7 are regulated by cellular ASF/SF2, itself defined as a
proto-oncogene and overexpressed in cervical cancer cells. We show that the most frequently used 3-splice site
on the HPV-16 genome, site SA3358, which is used to produce primarily E4, E6, and E7 mRNAs, is regulated
by ASF/SF2. Splice site SA3358 is immediately followed by 15 potential binding sites for the splicing factor
ASF/SF2. Recombinant ASF/SF2 binds to the cluster of ASF/SF2 sites. Mutational inactivation of all 15 sites
abolished splicing to SA3358 and redirected splicing to the downstream-located, late 3-splice site SA5639.
Overexpression of a mutant ASF/SF2 protein that lacks the RS domain, also totally inhibited the usage of
SA3358 and redirected splicing to the late 3-splice site SA5639. The 15 ASF/SF2 binding sites could be
replaced by an ASF/SF2-dependent, HIV-1-derived splicing enhancer named GAR. This enhancer was also
inhibited by the mutant ASF/SF2 protein that lacks the RS domain. Finally, silencer RNA (siRNA)-mediated
knockdown of ASF/SF2 caused a reduction in spliced HPV-16 mRNA levels. Taken together, our results
demonstrate that the major HPV-16 3-splice site SA3358 is dependent on ASF/SF2. SA3358 is used by the most
abundantly expressed HPV-16 mRNAs, including those encoding E6 and E7. High levels of ASF/SF2 may
therefore be a requirement for progression to cervical cancer. This is supported by our earlier findings that
ASF/SF2 is overexpressed in high-grade cervical lesions and cervical cancer.
Human papillomavirus type 16 (HPV-16) is the foremost
cause of cervical cancer, which is one of the most common
cancers in women globally (10, 37). Persistence of high-risk
HPV types, such as HPV-16, is the highest risk factor for the
development of cervical cancer. The majority of all DNA vi-
ruses that establish persistence have evolved a highly organized
gene expression program, often divided into clear early and
late phases. The HPV-16 genome contains an early promoter
that could potentially express mRNAs encoding all viral gene
products, and a late differentiation-dependent promoter that
specifically excludes expression of E6 and E7 (21). The switch
from early to late gene expression includes a promoter switch
as well as derepression and activation of the late poly(A) signal
and late splice sites (16). To activate late splice sites and the
late poly(A) signal, many early splice sites and the early
poly(A) signal must be downregulated to allow for competition
from mutually exclusive late splice sites and poly(A) signal (8,
26, 36). Other HPV-16 splice sites are used by both early and
late mRNAs and should function well in both mitotic cells and
terminally differentiated cells. One of the major splice sites
used by both early and late mRNAs is SA3358 (Fig. 1A). This
splice site is outstanding in that it is used to produce the
majority of all HPV-16 mRNAs, including the mRNAs of the
oncogenes E6 and E7 and the E4, E5, L1, and perhaps L2
proteins. In contrast, efficient usage of SA3358 specifically
prevents expression of HPV-16 E1 and E2.
Many, if not all, HPV types contain a 3-splice site in the E4
open reading frame (orf) that is spliced to an upstream 5-
splice site that joins the E1 AUG with the E4 orf. In HPV-16,
these splice sites are named SA3358 and SD880 (Fig. 1A),
whereas they are named SD847 and SA3325 in HPV-11 and
SD877 and SA3295 in HPV-31 (1). Splicing between HPV-16
SD880 and SA3358 (6, 9, 27), or the corresponding sites in
HPV-11 (5, 20, 23) and HPV-31 (11, 12), occurs on the most-
common early mRNAs encoding E6 and E7, as well as on the
most-abundant late mRNA encoding E4. In addition, the
most-common L1 mRNA is also spliced between SD880 and
SA3358 (17), or the corresponding sites in HPV-11 (23) and
HPV-31 (12, 22). Analysis of HPV-16 splicing in cervical
scrape samples revealed that splicing between SD880 and
SA3358 was the most-common splicing event in both low- and
high-grade cervical lesions (25). In vitro transfection experi-
ments demonstrated that splicing to SA3358 was required for
efficient expression of E6 and E7 (2). As a matter of fact,
splicing between SD880 and SA3358 was required for produc-
tion of E6 and E7 quantities that were needed for transforma-
tion of cells by these HPV proteins. In HPV-31, SA3295 cor-
responds to HPV-16 SA3358. Mutational inactivation of
HPV-31 SA3295 in an infectious molecular clone of HPV-31
immediately caused splicing to a cryptic 3-splice site located
three nucleotides further down (15). These results indicated
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FIG. 1. (A) Schematic representation of the HPV-16 genome. Early and late viral promoters p97 and p670 are indicated. Numbers indicate
nucleotide positions of 5-splice sites (filled circles), 3-splice sites (open circles), or early and late poly(A) signals pAE and pAL, respectively. LCR, long
control region. A few selected early and late mRNAs are shown (1). Previously described splicing silencers and enhancers are indicated (24, 34, 35).
(B) Diagram with potential ASF/SF2 sites upstream and downstream of SD3632 predicted by ESEfinder (4). Heights of the bars represent degrees of
similarity to ASF/SF2 binding sites according to ESEfinder. HPV-16 splice sites SA3358 and SD3632 are indicated. Numbers indicate nucleotide positions
in the HPV-16 genome. The position of a previously described enhancer is indicated (24). (C) ASF/SF2 sites in the mutant HPV-16 sequence in which
the ASF/SF2 sites had been inactivated, as predicted by ESEfinder (4). (D) Exact sequences of the wt and mutant (mut) HPV-16 Predicted sequences
between nucleotide positions 3407 and 3627 in the HPV-16 genome. Dots represent identical nucleotides.
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that HPV-31 SA3295 is under the control of strong splicing
enhancer elements and that there is a strong pressure on the
virus to maintain a 3-splice site in that exact region.
We have previously reported that HPV-16 SA3358 has an
exceptionally poor 3-splice site sequence compared to a con-
sensus 3-splice site (24). This is due primarily to an almost
complete absence of an upstream row of uninterrupted pyri-
midines that normally characterize an efficiently utilized 3-
splice site. However, SA3358 is one of the most efficiently used
splice sites on the HPV-16 genome (24, 33). We have previ-
ously shown that utilization of HPV-16 SA3358 is totally de-
pendent on exonic sequences downstream of SA3358, and we
concluded that a splicing enhancer was located downstream of
SA3358 (24). Here, we have followed up these findings; we
demonstrate that the enhancer elements downstream of
HPV-16 SA3358 are binding sites for ASF/SF2, and we show
that ASF/SF2 enhances splicing to SA3358.
MATERIALS AND METHODS
Plasmids. pMT1SD was constructed by cleaving pT1SD (24) with SalI and
BssHII, filling in overhangs, and religation. pTEx4m was created by first PCR







GCAGGGGTTCACACGATCT-3) (Scandinavian Gene Synthesis AB). The
PCR fragment was cleaved with XbaI and BssHII and subcloned into pT1SD
(24), resulting in pTEx4m. pMTEx4m was constructed by cleaving pTEx4m with
SalI and BssHII, filling in overhangs, and religation. Plasmid pT7wtexon4 was
created by PCR amplifying a sequence from pBEL (35) with oligonucleotides
exon4wtSKpnI (5-GGGTACCCCAACCACCCCGCCGCGACCCATAC-3)
and exon4wtASXbaI (5-TTCTAGAAAATGTACTATGGGTGTAGTGTTA
C-3). The PCR fragment was cleaved with KpnI and XbaI and subcloned into
pUC19T7 (32), resulting in pT7wtexon4. pT7mutexon4 was created by PCR
amplifying a sequence from pTEx4m with oligonucleotides exon4mutSKpnI (5-
CGGTACCCCAACTCGTGTGCCGCGACCCATAC-3) and M3A (5-GGGC
CCAGGCCTCGACACTGCAGTATACAATGTACAATGCT-3). The PCR
fragment was cleaved with KpnI and XbaI and subcloned into pUC19T7 (32),
generating pT7mutexon4. Glutathione S-transferase (GST), GST-ASF/SF2, and
GST-ASFDRS were generated using pGEX-GST (GE Healthcare).
The following plasmids have been described previously: pBEL (35), pBELM
(35), pBEL-OPSA (35), pBSplice and pBSpliceM (30), pT1SD (24), pMT198
(29), pBearly97 (33), and pT1-5/GAR (A. Tranell, E. M. Fenyö, and S. Schwartz,
submitted). pASF/SF2, pASFDRS, and pAdE4orf4 are kind gifts from Göran
Akusjärvi, IMBIM, Uppsala University, Sweden.
Transfection and cell culture. Maintenance and transfections of HeLa cells
with Fugene 6 (Roche Molecular Biochemicals) have been described previously
(30).
RNA extraction, Northern blotting and radiolabeled DNA probe synthesis,
and RT-PCR. Cytoplasmic RNA was extracted using isoB/NP-40 buffer as de-
scribed previously (32). Northern blot analysis was carried out as described
previously (30). Reverse transcription-PCR (RT-PCR) with cytoplasmic RNA
was performed as previously described using oligonucleotides 757s (35), p97s
(33), and L1aM (35), E4A (35), or 135 (5-CCTCGAGCTACTTATCGTCGTC
ATCCTTGTAATCTGGTTTCTGAGAACAGATGGGGCACAC-3 ), as indi-
cated in the figures. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
cDNA was amplified as control using previously described primers (13).
siRNA-mediated knockdown of ASF/SF2. Transfections of HeLa cells with the
ASF/SF2 siGenome Smartpool-designed silencer RNA (siRNA) (Dharmacon)
was performed using Oligofectamine (Invitrogen) according to the manufactur-
er’s protocol. The sequences of the sense and antisense strands of the four
siRNA duplexes were as follows: ASF/SF2-1 sense, 5-GAAAGAAGAUAUG
ACCUAUUU-3; ASF/SF2-1 antisense, 5-AUAGGUCAUAUCUUCUUUCU
U-3; ASF/SF2-2 sense, 5-UAACUUACCUCCAGACAUCUU-3; ASF/SF2-2
antisense, 5-GAUGUCUGGAGGUAAGUUAUU-3; ASF/SF2-3 sense, 5-U
GAAGCAGGUGAUGUAUGUUU-3; ASF/SF2-3 antisense, 5-ACAUACAU
CACCUGCUUCAUU-3; ASF/SF2-4 sense, 5-CGACGGCUAUGAUUACG
AUUU-3; ASF/SF2-4 antisense, 5-AUCGUAAUCAUAGCCGUCGUU-3.
Briefly, HeLa cells were plated in regular growth medium in a six-well tissue
culture dish 24 h prior to transfection. The next day, cells were transfected with
133 nM siRNA mix in a total volume of 1.8 ml of serum- and antibiotic-free
Dulbecco’s modified Eagle’s medium (DMEM) with 4 l Oligofectamine. After
incubation for 4 h, 0.5 ml DMEM containing three times the normal concentra-
tion of antibiotics and fetal bovine serum was added to the transfected HeLa cells
without removal of the transfection mixture. At 24 h after siRNA transfection,
cells were transfected with 0.5 g of subgenomic HPV-16 plasmid pBELM (35).
At 72 h after the initial siRNA transfection, cytoplasmic RNA was extracted and
RT-PCR was performed. A total cell extract was used for Western blotting with
antibody mab65 (a kind gift of Göran Akusjärvi, Uppsala University, Sweden)
against ASF/SF2 to ascertain efficient ASF/SF2 knockdown.
Purification of recombinant GST proteins and UV cross-linking. Purification
of recombinant GST fusion proteins using glutathione-Sepharose (GS) was per-
formed as specified by the manufacturer (GE Healthcare). Plasmids pT7mutexon4
and pT7wtexon4 were individually linearized with XbaI and subjected to in vitro
transcription with T7 RNA polymerase in the presence of with [-32P]UTP. Each
RNA probe (105 cpm) was UV cross-linked to GST-ASF/SF2 or GST-ASFDRS as
previously described (28, 31).
RESULTS
Multiple ASF/SF2 binding sites downstream of SA3358.
SA3358 is one of the major 3-splice sites on the HPV-16
genome, and it is required for the production of all early
mRNAs, except E1 and E2 mRNAs, as well as L1 and L2
mRNAs (Fig. 1A). We have previously shown that SA3358 is
suboptimal and totally dependent on a downstream splicing
enhancer (24). However, splicing factors that regulate SA3358
have not been identified. We have used the ESEfinder pro-
gram (4) to search for potential SR-protein binding sites down-
stream of SA3358. Interestingly we found 15 potential ASF/
SF2 binding sites in the 275-nucleotide exon located between
SA3358 and SD3632, overlapping the previously identified
splicing enhancer (Fig. 1A and B) (24). In contrast, analysis of
the adjacent 275 nucleotides located downstream of SD3632
identified only three potential ASF/SF2 binding sites (Fig. 1B).
This analysis suggested that ASF/SF2 may play a role in the
regulation of SA3358. If these sites regulated SA3358, muta-
tional inactivation of the predicted ASF/SF2 sites would impair
splicing to SA3358. To test this idea, we mutationally inacti-
vated all 15 ASF/SF2 sites located between SA3358 and
SD3632. Analysis of the mutant sequence in ESEfinder (4)
revealed that the predicted ASF/SF2 sites were no longer rec-
ognized by ESEfinder (Fig. 1C). The exact nucleotide changes
are shown in the alignment of wild-type (wt) and mutant
HPV-16 sequence in Fig. 1D.
Mutational inactivation of all predicted ASF/SF2 sites
downstream of SA3358 inhibits the use of SA3358 and redi-
rects splicing to late splice acceptor SA5639. In order to in-
vestigate if mutational inactivation of the predicted ASF/SF2
binding sites downstream of SA3358 affected HPV-16 mRNA
splicing, we inserted all 15 mutations in subgenomic HPV-16
plasmid pBELM (Fig. 2A) (35), resulting in plasmid pTEx4m
(Fig. 2A). The pBELM plasmid has been described by us
previously (35). It produces high levels of E4 mRNA spliced
from SD880 to SA3358 and low levels of the L1 mRNAs as a
result of mutationally inactivated splicing silencers at the late
3-splice site SA5639 (35). Analysis of mRNA produced from
pBELM and pTEx4m in transfected HeLa cells confirmed that
pBELM produced high levels of E4 mRNA and low levels of
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FIG. 2. (A) Schematic representation of the HPV-16 genome and the subgenomic HPV-16 expression plasmids pBELM (35), pTEx4m, and
pT1SD (24). Numbers indicate nucleotide positions of 5-splice sites (filled circles) and 3-splice sites (open circles) or poly(A) sites pAE and pAL.
Structures of selected HPV-16 mRNAs produced by pBELM (35) are indicated below plasmids. Black bars represent E4 and L1 probes used for
Northern blotting. RT-PCR primers 757s, E4A, and L1aM are indicated. (B) Left panels, Northern blots of cytoplasmic RNA extracted from HeLa
cells transfected with pBELM, pT1SD (24), or pTEx4m. Blots were probed with L1 or E4 probe, as indicated. Gels were also probed for GAPDH.
Right panels, RT-PCR on the same RNA analyzed by RT-PCR using primers 757s and L1aM or 757s and E4A (35). The E4A primer hybridizes
to a sequence that is present in all three plasmids and that is unaffected by the nucleotide substitutions in pTEx4m.
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L1 mRNAs, as expected (Fig. 2B). In contrast, pTEx4m did not
produce detectable levels of E4 mRNAs (Fig. 2B), suggesting
that usage of SA3358 was totally dependent on the ASF/SF2
sites. Interestingly, the decrease in E4 mRNA production for
pTEx4m was paralleled by an increase in L1i mRNA produc-
tion (Fig. 2A and B). Northern blot and RT-PCR analysis
showed that mutational inactivation of the potential ASF/SF2
binding sites redirected splicing from SA3358 to late splice
acceptor SA5639 (Fig. 2A and B). Similar results were ob-
tained when the sequences downstream of SA3358 were de-
leted as in plasmid pT1SD (Fig. 2A and B) (24). Endogenous
HPV-18 sequences in HeLa cells do not interfere with the
assays described here, as HPV-16 primers and probes are spe-
cific for HPV-16. In addition, some of the experiments have
been reproduced with HPV-negative cell lines, such as 293T
cells, with similar results. Taken together, our results indicated
that the potential ASF/SF2 sites were required for splicing to
SA3358.
ASF/SF2 binds specifically to exonic sequences located be-
tween SA3358 and SD3632. To determine if ASF/SF2 binds
directly to the predicted ASF/SF2 sites in the sequence be-
tween SA3358 and SD3632, GST-ASF was UV cross-linked to
radiolabeled RNA representing the wt or mutant sequences
shown in Fig. 1D. The results revealed that GST-ASF UV
cross-linked efficiently to this HPV-16 sequence, whereas GST
did not (Fig. 3A). GST-ASF did not UV cross-link to an RNA
sequence derived from the HPV-1 late untranslated region
(UTR) (data not shown). Cross-linking to the mutant RNA
was less efficient, as expected (Fig. 3A). However, UV cross-
linking of ASF/SF2 to the mutant RNA is probably overesti-
mated by the gel, as the mutant RNA contains 72 radiolabeled
U nucleotides, whereas the wt RNA contains only 36 (Fig. 1D).
We concluded that ASF/SF2 binds directly to the sequence
located between HPV-16 SA3358 and SD3632.
Overexpression of the ASF/SF2 RS mutant inhibits usage of
SA3358. To confirm that ASF/SF2 acts via the ASF/SF2 sites in
the enhancer region, we used an ASF/SF2 mutant that lacks
the RS-domain (ASFDRS) and therefore binds RNA but fails
to activate splicing. The ASFDRS trans-dominant mutant
should compete with endogenous ASF/SF2 for the ASF/SF2
binding sites and inhibit splicing to SA3358. UV cross-linking
of serially diluted GST-ASF or GST-ASFDRS to radiola-
beled wt HPV-16 RNA, shown in Fig. 1D, revealed that the
two proteins cross-linked to this RNA sequence with similar
efficiency (Fig. 3B and C). In addition, overexpression of
ASFDRS in transfected cells inhibited splicing to SA3358 in
plasmid pBELM, thereby inhibiting production of E4
mRNA (Fig. 4B). Overexpression of ASFDRS also caused a
redirection of splicing from SA3358 to SA5639, thereby
inducing L1i mRNA production (Fig. 4C). Overexpression
of ASFDRS therefore causes the same phenotype as muta-
tional inactivation of ASF/SF2 sites at SA3358 in pTEX4m
(compare Fig. 2B and 4C). This result is seen only when
SA5639 is optimized either by mutational inactivation of
splicing silencers located downstream of SA5639 or by direct
optimization of the 5639 polypyrimidine tract as in pBEL-
OPSA (Fig. 4C and D). Therefore, ASFDRS cannot induce
splicing to wt SA5639 in pBEL since it is suppressed by
previously identified splicing silencers (Fig. 4C). RT-PCR
confirmed that ASFDRS induced L1i by exon skipping (Fig.
4E). This effect is clearly distinct from the induction of L1
mRNA production by the adenovirus E4orf4 protein, as
previously described (Fig. 4E) (29).
Overexpression of ASFDRS did not induce L1 production
from pT1SD or pTEx4m (Fig. 4F), in which the ASF/SF2
binding sites had been either deleted or mutationally inacti-
vated. These results indicated that redirection of splicing to
SA5639 by ASFDRS was dependent on the ASF/SF2 binding
sites in the enhancer region downstream of SA3358. In con-
trast, a small inhibitory effect on L1i mRNA levels was seen
when ASFDRS was overexpressed (Fig. 4G). This result sug-
gested that ASFDRS inhibited SA5639 and will be discussed
below. We concluded that ASFDRS inhibits the ability of en-
dogenous ASF/SF2 to enhance splicing to SA3358 and that this
inhibition was dependent on intact ASF/SF2 sites in the en-
hancer region downstream of SA3358.
Our results suggested that E6/E7 mRNAs are also regulated by
ASF/SF2, as it has been shown previously that the most-common
E6 and E7 mRNAs that are spliced between SD226 and SA409 or
SA526 are also spliced between SD880 and SA3358. As such, they
would be dependent on ASF/SF2. To investigate if this was the
FIG. 3. (A) UV cross-linking of GST or GSTASF to the in vitro
synthesized, radiolabeled wt and mutant HPV-16 RNAs shown in
Fig. 1D. UV cross-linking of serially diluted GST-ASF (B) or GST-
ASFDRS (C) to radiolabeled wt HPV-16 RNA shown in Fig. 1D.
Molecular weights (MW; in thousands) are indicated on the left.
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case, plasmid pBearly97 (Fig. 4F) was transfected into HeLa cells
in the absence or presence of the mutant ASF protein named
ASFDRS. If the E6/E7 mRNAs are regulated by ASF/SF2, over-
expression of ASFDRS should inhibit the production of these
mRNAs. As can be seen in Fig. 4F, E6/E7 mRNAs that are
spliced between SD226 and SA409 or SA526 were negatively
affected by ASFDRS but not by transfection with an empty ex-
pression plasmid (Fig. 4F). We concluded that expression of E6
and E7 mRNAs is dependent on ASF/SF2.
The ASF/SF2-dependent HIV-1 splicing enhancer termed
GAR can substitute for the HPV-16 enhancer at SA3358. To
provide further support for a role of ASF/SF2 in the regulation
of HPV-16 SA3358, we inserted the ASF/SF2-dependent GAR
enhancer from HIV-1 (3), into the enhancerless HPV-16 plas-
mid pT1SD (Fig. 5A) (24). As can be seen in Fig. 5B and C,
pT1SD produced only L1i mRNA, as SA3358 was not used,
whereas pT1-5/GAR, in which the ASF/SF2-dependent GAR
enhancer had been inserted, produced only L1 mRNA as a
result of efficient usage of SA3358 (Fig. 5B and C). We con-
cluded that splicing to HPV-16 SA3358 could be restored by
a heterologous but ASF/SF2-dependent enhancer, support-
ing the conclusion that ASF/SF2 regulates HPV-16 SA3358.
Overexpression of ASFDRS with pT1-5/GAR induced pro-
duction of L1i mRNA (Fig. 5B and C), indicating that
FIG. 4. (A) Schematic representation of the HPV-16 genome and the subgenomic HPV-16 expression plasmids pBEL (35), pBELM (35),
pBEL-OPSA (35), pT1SD (24), and pTEx4m. Numbers indicate nucleotide positions of 5-splice sites (filled circles) and 3-splice sites (open
circles) or poly(A) sites pAE and pAL. Structures of selected HPV-16 mRNAs produced by pBELM (35) are indicated below plasmids. Black
bars represent E4 and L1 probes used for Northern blotting. RT-PCR primers 757s and L1aM are indicated (35). CMV, cytomegalovirus.
(B to D and G) Northern blots of cytoplasmic RNA extracted from HeLa cells transfected with the indicated plasmids in the absence or
presence of ASFDRS-expressing plasmid. Blots are probed with E4 or L1 probe as indicated. Gels were also probed for GAPDH. Positions
of the E4 and L1 or L1i mRNAs are indicated. (E) RT-PCR on cytoplasmic RNA from HeLa cells transfected with pBELM in the presence
of ASFDRS expression plasmid or adenovirus E4orf4 expression plasmid. The RNA samples were analyzed by RT-PCR using primers 757s
and L1aM (35). (F) Left panel, schematic drawing of plasmid pBeary97 (33). Right panel, RT-PCR on cytoplasmic RNA from HeLa cells
transfected with pBeary97 in the absence or presence of ASFDRS expression plasmid. The RNA samples were analyzed by RT-PCR using
primers p97s and 135 (35).
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ASFDRS interferes with the enhancer function of GAR. In con-
trast, ASFDRS did not alter splicing in pT1SD (Fig. 5C) as
expected, since ASF/SF2 sites had been deleted. These data
strengthened the conclusion that ASF/SF2 enhances splicing to
SA3358.
ASF/SF2 contributes to the suppression of splice donor
SD3632. To investigate if the ASF/SF2 binding sites located be-
tween SA3358 and SD3632 contribute to suppression of SD3632,
we constructed pMT1SD and pMTEx4m from pBSpliceM (Fig.
6A) (30). pBSpliceM does not produce detectable levels of E4 or
L1 mRNA in the absence of transacting factors, e.g., PTB or
AdE4orf4 (Fig. 6B) (29, 30). These plasmids contain a large
deletion between nucleotide position 757 and 3395 in the early
region of the HPV-16 genome which removes all HPV-16
splice sites except late splice sites SD3632 and SA5639 (Fig.
6A). In addition, the ASF/SF2 binding sites upstream of
SD3632 were either deleted (pMT1SD) or mutationally inac-
tivated (pMTEx4m) (Fig. 6B). Transfection of pMT1SD and
pMTEx4m into HeLa cells and analysis of mRNA production
showed that pMT1SD produced high L1 mRNA levels,
whereas L1 mRNA production from pMTEx4m was less ele-
vated than that from pBSpliceM (Fig. 6B). These results indi-
cated that sequences located between nucleotide positions
3395 and SD3632 strongly suppressed SD3632. However, mu-
tations of the potential ASF/SF2 binding sites upstream of
SD3632 only partially alleviated inhibition, indicating that
ASF/SF2 contributes to inhibition of SD3632, although addi-
tional factors must be involved as well.
To investigate if ASF/SF2 indeed inhibits SD3632, we mon-
itored the effect of ASFDRS on HPV-16 plasmids pBSplice
and pBSpliceM (Fig. 6A) (30). Transfection of pBSplice or
pBSpliceM in the absence or presence of ASFDRS showed
that ASFDRS induced L1 mRNA from pBSpliceM but not
from pBSplice (Fig. 6C). These results suggested that either wt
ASF/SF2 inhibits SD3632 or ASF/SF2 can activate SD3632 in
an RS domain-independent manner. To differentiate between
these two possibilities, we overexpressed a similar level of ASF/
SF2 or ASFDRS with pBSpliceM. The results revealed that
ASFDRS induced high levels of L1, whereas L1 mRNA was
undetectable in the presence of ASF/SF2 (Fig. 6D). ASFDRS
FIG. 5. (A) Schematic representation of the HPV-16 genome and the subgenomic HPV-16 expression plasmids pBELM (35), pT1SD (24), and
pT1-5/GAR. Numbers indicate nucleotide positions of 5-splice sites (filled circles) and 3-splice sites (open circles) or poly(A) sites pAE and pAL.
The location of a previously identified splicing enhancer in the HPV-16 genome is indicated (24). The inserted HIV-1 sequence encompassing
GAR, a previously identified splicing enhancer in the HIV-1 genome (3), is indicated. Structures of selected HPV-16 mRNAs produced by pBELM
are indicated below plasmids. Black bar represents the L1 probe used for Northern blotting. RT-PCR primers 757s and L1aM are indicated (35).
(B) Northern blot of cytoplasmic RNA extracted from HeLa cells transfected with pT1-5/GAR or pT1SD (24) in the absence or presence of
ASFDRS-expressing plasmid. Blot was probed with L1 probe. (C) RT-PCR on the same RNA analyzed by RT-PCR using primers 757s and L1aM.
L1 and L1i mRNAs are indicated.
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also caused an increase in L1 expression from pMTEx4m (Fig.
6E). Therefore, ASFDRS either inhibited independently of the
ASF/SF2 binding sites upstream of SD3632, or ASFDRS could
still bind to the sequences upstream of SD3632. Nevertheless,
ASFDRS induced splicing from SD3632, indicating that ASF/SF2
therefore inhibits SD3632. To investigate if inhibition of SD3632
was mediated by the potential ASF/SF2 sites located downstream
of SD3632 (Fig. 1B), two of the three sites were deleted in pM198
(Fig. 6A). This plasmid did not produce detectable levels of L1,
and overexpression of ASFDRS resulted in induction of L1 (Fig.
6F). We concluded that sequences between SD3632 and pAE did
not inhibit SD3632, nor were they targeted by ASF/SF2. We
concluded that ASF/SF2 exerts an inhibitory effect on SD3632,
but other factors are major inhibitors of SD3632.
ASF/SF2 can induce splicing to SA5639 but less efficiently
than to SA3358. As we described previously, mutations or
deletions of the ASF/SF2 binding sites downstream of SA3358
resulted in redirection of splicing to SA5639 (Fig. 2B and 4G).
However, these plasmids were not indifferent to ASFDRS
overexpression, although the ASF/SF2 sites at SA3358 had
been inactivated (Fig. 4G and 5B). Careful quantitations of L1
mRNA levels produced by these mutants in the absence or
presence of ASFDRS revealed that ASFDRS actually reduced
L1 mRNA production from pTEx4m (Fig. 4F) and pT1SD
FIG. 6. (A) Schematic representation of the HPV-16 genome and the subgenomic HPV-16 expression plasmids pBSplice (30), pBSpliceM (30),
pMT1SD, pMTEx4m, and pMT198. Numbers indicate nucleotide positions of 5-splice sites (filled circles) and 3-splice sites (open circles) or
poly(A) sites pAE and pAL. Structures of selected HPV-16 mRNAs produced by pBELM (35) are indicated below plasmids. Black bar represents
L1 probe used for Northern blotting. (B to F) Northern blots of cytoplasmic RNA extracted from HeLa cells transfected with the indicated
plasmids in the absence or presence of ASFDRS-expressing plasmid. Blots are probed with L1 probe. Gels were also probed for GAPDH. Position
of the L1 mRNA is indicated.
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(Fig. 4G and 5B). We concluded that splicing to SA5639 was
inhibited by ASFDRS, suggesting that SA5639 also was af-
fected by ASF/SF2.
If ASFDRS inhibits splicing from SD880 to both SA3358
and SA5639, the net effect of ASFDRS should be dependent
on the concentration of ASFDRS. pBELM (35) was trans-
fected with a serial dilution of ASFDRS plasmid. The results
revealed that induction of L1 expression was dependent upon
the amount of ASFDRS expression plasmid transfected (Fig.
7A). Optimal induction by inhibition of SA3358 occurred at a
concentration of 0.5 g of ASFDRS plasmid, whereas higher
concentrations of ASFDRS reduced L1 mRNA levels, presum-
ably by inhibiting SA5639 (Fig. 7A). Similar results were seen
with two different concentrations of ASFDRS (Fig. 6D). We
concluded that ASFDRS inhibits both SA3358 and SA5639. As
a consequence, ASF/SF2 should have a positive effect on splic-
ing to SA5639. To investigate if ASF/SF2 could induce L1
mRNA production, we overexpressed ASF/SF2 with plasmids
pBEL and pBELM. Transfection of a 2-fold serial dilution of
ASF/SF2 plasmid, ranging from 4 g to 0.25 g, induced L1
expression from neither pBELM nor pBEL (data not shown).
In contrast, submicrogram levels of ASF/SF2 plasmid induced
L1 mRNA from both pBELM and pBEL (Fig. 7B and C). The
induced L1 mRNA levels were higher from pBELM (Fig. 7B)
than from pBEL (Fig. 7C), demonstrating that ASF/SF2 could
not overcome suppression of SA5639 very efficiently. The fail-
ure of high levels of ASF/SF2 to induce L1 mRNA production
was expected, since ASF/SF2 also stimulates splicing to the
competing 3-splice site SA3358 and has an inhibitory effect on
SD3632. We concluded that ASF/SF2 could stimulate splicing
to SA5639, albeit with low efficiency.
Knockdown of ASF/SF2 reduces splicing to SA3358 and
SA5639. We also wished to determine if ASF/SF2 was needed
for splicing to SA3358 and SA5639. We therefore knocked
down endogenous ASF/SF2 using siRNAs against ASF/SF2.
We reasoned that siRNA-mediated knockdown of ASF/SF2
should inhibit the production of E4, L1, and L1i mRNAs. As
can be seen in Fig. 8A, a Western blot shows successful knock-
down of ASF/SF2 in cells transfected with pBELM. As ex-
pected, E4, L1, and L1i mRNA levels were reduced when
ASF/SF2 was knocked down (Fig. 8B). The E4 mRNA is sup-
pressed to a lower extent, probably because E4 mRNAs are
more abundantly expressed from pBELM than is the L1
mRNA (Fig. 8B). These results confirmed that splicing to both
SA3358 and SA5639 is enhanced by ASF/SF2.
DISCUSSION
It has been shown previously that ASF/SF2 is a proto-onco-
gene that can transform rodent cells in vitro and that it is
overexpressed in various cancers (14). We have shown that a
number of RNA-binding proteins, including splicing factor
FIG. 7. (A) Northern blot of cytoplasmic RNA extracted from HeLa
cells transfected with pBELM (35) in the absence or presence of serially
diluted ASFDRS-expressing plasmid (0.25 to 4 g). Blot was probed with
L1 probe. (B) Northern blot of cytoplasmic RNA extracted from HeLa
cells transfected with pBELM (35) in the absence or presence of serially
diluted ASF/SF2-expressing plasmid (10 to 160 ng). Blot was probed with
L1 probe. Numbers indicate nanograms of ASF/SF2 plasmid used in the
transfection. Blot was probed with L1 probe. Positions of the L1 and L1i
mRNAs are indicated. Lower panel, quantitation of the L1 bands in
the gel using phosphorimager. (C) Northern blot of cytoplasmic RNA
extracted from HeLa cells transfected with pBEL (35) in the absence
or presence of serially diluted ASF/SF2-expressing plasmid (10 to 160
ng). Blot was probed with L1 probe. Numbers indicate nanograms of
ASF/SF2 plasmid used in the transfection. Blot was probed with L1
probe. Positions of the L1 mRNA are indicated.
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ASF/SF2, are overexpressed in cervical cancers (7). As a mat-
ter of fact, ASF/SF2 expression increased with the grade of
severity of the cervical lesion induced by HPV, as did expres-
sion of most RNA binding proteins (7). Relatively few cells
expressed ASF/SF2 in normal HPV-negative cervical epithe-
lium (7). These cells were found in the basal cell layers as well
as in suprabasal layers but not in the superficial layers of the
epithelium. In contrast, ASF/SF2 was abundantly expressed in
the entire epithelium for high-grade, CIN-III cervical intraepi-
thelial lesions and all cervical cancers (7). Mole et al. also
observed higher levels of expression of ASF/SF2 in high-grade
lesions compared to those in low-grade lesions (18). Taken
together, these results suggest that cancer cells, as well as some
HPV-16 genes, benefit from a high expression level of ASF/
SF2. As ASF/SF2 is a key regulator of RNA processing, high
expression in cancer cells may reflect the high metabolic activ-
ity of these cells and a need for high and efficient expression of
many genes. In case of HPV-16, ASF/SF2 is required primarily
for splicing to SA3358. This splicing event removes the intron
between SD880 and SA3358 or that between SD226 and
SA3358, resulting in the production of HPV-16 mRNAs that
are efficiently expressed in HPV-16-infected cells (Fig. 1).
HPV-16 E6 and E7 mRNAs that are spliced between SD880
and SA3358 are vastly more common than those that retain the
intron between SD880 and SA3358 (9, 17, 24, 35). In general,
intron-containing mRNAs are retained and degraded in the
nucleus to a higher degree than spliced mRNAs, which may
explain the low levels of HPV-16 mRNAs that contain se-
quences between SD880 and SA3358. One may therefore con-
clude that mRNAs that are spliced between SD880 and
SA3358 benefit from high levels of ASF/SF2 (Fig. 9). Such
mRNAs encode E6, E7, or E4 proteins, and the shorter forms
of E6 named E6*-I and E6*-II, depending on the upstream
splicing events on these mRNAs (Fig. 1A). Similarly, mRNAs
that are spliced between SD226 and SA3358, and have the
potential to produce E5 protein (Fig. 1A), would benefit from
high levels of ASF/SF2. Of the early HPV-16 mRNAs that are
selectively stimulated by high levels of ASF/SF2, there is an
overrepresentation of mRNAs that express viral cell growth-
stimulatory proteins, including E5, E6, and E7. This deduction
fits well with the previously observed high expression levels of
ASF/SF2 in high-grade cervical lesions and cervical cancers
(7). It was previously reported that HPV-16 E2 enhances ASF/
SF2 expression by transcriptional activation of the ASF/SF2
promoter (19). Here, we report that ASF/SF2 induces splicing
to SA3358 on the HPV-16 genome. Interestingly, splicing to
SA2709, the splicing event that generates E2 mRNAs, and
splicing to SA3358 are two mutually exclusive events (Fig. 1A).
High levels of ASF/SF2 may therefore downregulate expres-
sion of E2, presumably in a negative feedback manner, perhaps
marking the entry into the late phase of the viral life cycle with
L1 and L2 expression.
As HPV-16 enters the late stage of the viral life cycle and the
infected cell differentiates terminally, suppression of the exclu-
sively late splice sites SD3632 and SA5639 is released and
efficiency of early polyadenylation reduced. These events cause
induction of L1 and L2 mRNA production. However, SA3358
must be efficiently used also in these cells, as it is used by late
L1 mRNAs. This would require the presence of ASF/SF2 also
in terminally differentiated cells. Alternatively, the role of
ASF/SF2 is taken over by another, yet-unidentified splicing
factor that is present in terminally differentiated cells. As ASF/
SF2 is normally not detected in the upper layers of uninfected
cervical epithelium, this may indeed be the case (7). However,
one may speculate that HPV-16 selectively enhances produc-
tion of ASF/SF2, even in the terminally differentiated cells in
which L1 and L2 protein can be detected. This could be per-
formed by E2 or indirectly by another HPV protein. It would
be interesting to compare expression of ASF/SF2 and HPV-16
L1 and L2 expression in individual cells in HPV-16-infected
cervical epithelium to determine if ASF/SF2 is present in the
cells that express L1 and/or L2 protein. In addition, it would be
of interest to determine if the dependence on ASF/SF2 is
conserved among different HPV types. We have found that the
ESEfinder (4) predicts the presence of multiple ASF/SF2 sites
in the corresponding position of both low-risk and high-risk
HPV types and in mucosal and cutaneous HPV types. We
FIG. 8. (A) Western blot of cell extracts from HeLa cells trans-
fected with pBELM in the absence or presence of siRNAs against
ASF/SF2, as described in Materials and Methods. (B and C) RT-PCR
on cytoplasmic RNA extracted from HeLa cells transfected with
pBELM (35) in the absence or presence of siRNA against ASF/SF2.
RT-PCR was performed with primers 757s and L1aM (B) or 757s and
E4A (C) (35). RT-PCR was also performed with GAPDH mRNA
(C) (13). Structures of the L1 and L1i mRNAs, or the E4 mRNA, are
shown to the right of the gels. Numbers indicate positions of splice sites
on the mRNAs. M, molecular size marker.
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therefore believe that ASF/SF2 regulates splicing of both low-
and high-risk HPV types.
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